XRCC1 codon 399 mutant allele: A risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy

Cancer Biology and Therapy

Volumn 7, Issue 5, 2008, Pages 647-652

  Mittal, Rama Devi ^a   Singh, Ranjana ^a   Manchanda, Parmeet Kaur ^a   Ahirwar, Dinesh ^a   Gangwar, Ruchika ^a   Kesarwani, Pravin ^a   Mandhani, Anil ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

BCG; Bladder cancer; Bladder cancer recurrence; DNA repair; Immunotherapy; PCR RFLP; Polymorphism; XRCC1

Indexed keywords

BCG VACCINE; XRCC1 PROTEIN; DNA BINDING PROTEIN; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1;

ADULT; ARTICLE; BLADDER CANCER; CANCER RECURRENCE; CANCER RISK; CANCER SUSCEPTIBILITY; DISEASE ASSOCIATION; DNA POLYMORPHISM; EXCISION REPAIR; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HIGH RISK POPULATION; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROTEIN STRUCTURE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; XRCC1 CODON 399 MUTANT ALLELE; AGED; ALLELE; BIOSYNTHESIS; BLADDER TUMOR; CHEMISTRY; CODON; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; MUTATION; RISK; RISK FACTOR; UROTHELIUM;

AGED; ALLELES; BCG VACCINE; CODON; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; MUTATION; RISK; RISK FACTORS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 56149116930     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Parkin DM. International variation. Oncogene 2004; 23:6329-40.
2. Cohen SM, Shirai T, Steineck,G. Epidemiology and etiology of premalignant and malignant urothelial changes. Scand J Urol Nephrol Suppl 2000; 205:105-15.
3. Shields PG, Harris CC. Cancer risk and low-penetrance susceptibility genes in gene environment interactions. J Clin Oncol 2000; 18:2309-15.
4. Wu X, Zhao H, Suk R, Christiani DC. Genetic susceptibility to tobacco-related cancer. Oncogene 2004; 23:6500-23.
5. Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 2000; 92:874-97.
6. Caldecott KW. XRCC1 and DNA strand break repair. DNA Repair (Amst) 2003; 2:955-69.
7. Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 1998; 58:604-8.
8. Stern MC, Umbach DM, Lunn RM, Taylor JA. DNA repair gene XRCC3 codon 241 polymorphism, its interaction with smoking and XRCC1 polymorphisms, and bladder cancer risk. Cancer Epidemiol. Biomarkers Prev 2002; 11:939-43.
9. Kelsey KT, Park S, Nelson HH, Karagas MR. A population-based case-control study of the XRCC1 Arg399Gln polymorphism and susceptibility to bladder cancer. Cancer Epidemiol Biomarkers Prev 2004; 13:1337-41.
10. Martin ER, Lai EH, Gilbert JR, Rogala AR, Afshari AJ, Riley J, Finch KL, Stevens JF, Livak KJ, Slotterbeck BD, Slifer SH, Warren LL, Conneally PM, Schmechel DE, Purvis I, Pericak Vance MA, Roses AD, Vance JM. SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease. Am J Hum Genet 2000; 67:383-94.
11. Fleming ID, Sobin LH. TNM Classification of Malignant Tumors, fifth edition. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997; 80:1803-4.
12. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215.
13. Chacko P, Rajan B, Joseph T, Mathew BS, Pillai MR. Polymorphisms in DNA repair gene XRCC1 and increased genetic susceptibility to breast cancer. Breast Cancer Res Treat 2005; 89:15-21.
14. Pitard A, Brennan P, Clavel J, Greiser E, Lopez-Abente G, Chang-Claude J, Wahrendorf J, Serra C, Kogevinas M, Boffetta P. Cigar, pipe, and cigarette smoking and bladder cancer risk in European men. Cancer Causes Control 2001; 12:551-6.
15. Taylor JA, Umbach DM, Stephens E, Castranio T, Paulson D, Robertson C, Mohler JL, Bell DA. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. Cancer Res 1998; 58:3603-10.
16. Larsson P, Wijkstrom H, Thorstenson A, Adolfson J, Norming U, Wiklund Ponelov E, Steineck J. A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years. Scand J Urol Nephrol 2003; 37:195-201.
17. Vijjan V, Mandhani A, Kapoor R, Dubey D, Srivastava A, Ansari MS, Singh P, Kumar A. Randomized trial comparing low dose (40 or 80 mg) with standard dose (120 mg) of bacillus Calmette-Guerin for superficial bladder cancer. Ind J Urol 2006; 22:317-21.
18. Demkow T, Alter A, Wiechno P. Intravesical bacillus Calmette- Guérin therapy for T1 superficial bladder cancer. Urol Int 2008; 80:74-9.
19. Hoeijmakers JHJ. Genome maintenance mechanisms for preventing cancer. Nature (London) 2001; 411:366-74.
20. Hu Z, Ma H, Chen F, Wei Q, Shen H. XRCC1 polymorphisms and cancer risk: a meta-analysis of 38 case-control studies. Cancer Epidemiol Biomarkers Prev 2005; 14:1810-8.
21. Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 1999; 59:2557-61.
22. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11:1513-30.
23. Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, Norming U, Wijkström H, Larsson P, Kumar R, Hemminki K. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis 2004; 25:729-34.
24. Wu X, Gu J, Grossman HB, Amos CI, Etzel C, Huang M, Zhang Q, Millikan RE, Lerner S, Dinney CP, Spitz MR. Bladder Cancer Predisposition: A Multigenic Approach to DNA-Repair and Cell Cycle-Control Genes. Am J Hum Genet 2006; 78:464-79.
25. Andrew AS, Nelson HH, Kelsey KT, Moore JH, Meng AC, Casella DP, Tosteson TD, Schned AR, Karagas MR. Concordance of multiple analytical approaches demonstrates a complex relationship between DNA repair gene SNPs, smoking and bladder cancer susceptibility. Carcinogenesis 2006; 27:1030-7.
26. Stern MC, Umbach DM, van Gils CH, Lunn RM, and Taylor JA. DNA Repair Gene XRCC1 Polymorphisms, Smoking, and Bladder Cancer Risk. Cancer Epidemiol Biomarkers Prev 2001; 10:125-31.
27. Shen M, Hung R J, Brennan P, Malaveille C, Donato F, Placidi D, Carta A, Hautefeuille A, Boffetta P and Porru S. Polymorphisms of the DNA Repair Genes XRCC1, XRCC3, XPD, Interaction with Environmental Exposures, and Bladder Cancer Risk in a Case-Control Study in Northern Italy. Cancer Epidemiol Biomarkers Prev 2003; 12:1234-40.
28. Böhle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003; 170:964-9.
29. Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 1999; 59:2557-61.